AR099625A1 - Anticuerpos de il-21 - Google Patents
Anticuerpos de il-21Info
- Publication number
- AR099625A1 AR099625A1 ARP150100643A ARP150100643A AR099625A1 AR 099625 A1 AR099625 A1 AR 099625A1 AR P150100643 A ARP150100643 A AR P150100643A AR P150100643 A ARP150100643 A AR P150100643A AR 099625 A1 AR099625 A1 AR 099625A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- antibody
- sequence
- chains
- mammalian cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicación 1: Un anticuerpo que se une a IL-21 humana caracterizado porque comprende una región variable de cadena pesada (HCVR) y una región variable de cadena ligera (LCVR) en donde la LCVR comprende la SEQ ID Nº 7 en la CDRL1, la SEQ ID Nº 8 en la CDRL2 y la SEQ ID Nº 9 en la CDRL3 y en donde la HCVR comprende la SEQ ID Nº 10 en la CDRH1, la SEQ ID Nº 11 en CDRH2 y la SEQ ID Nº 12 en la CDRH3. Reivindicación 5: Una molécula de ADN caracterizada. porque comprende un polinucleótido que codifica la cadena pesada de anticuerpo cuya secuencia de aminoácido es la secuencia de la SEQ ID Nº 3. Reivindicación 11: Una célula de mamífero transformada con la molécula de ADN de conformidad con la reivindicación 5 o reivindicación 6 y la molécula de ADN de conformidad con la reivindicación 7 o reivindicación 9, caracterizada porque la célula de mamífero transformada es capaz de expresar un anticuerpo que comprenden dos cadenas pesadas de anticuerpo y dos cadenas ligeras de inmunoglobulina, en las cuales la secuencia amino de cada una de las dos cadenas pesadas es la secuencia de la SEQ ID Nº 3 y la secuencia de aminoácido de cada una de las dos cadenas ligeras es la secuencia de la SEQ ID Nº 4. Reivindicación 13: Un proceso para producir un anticuerpo, en el cual el anticuerpo comprende dos cadenas pesadas de anticuerpo y dos cadenas ligeras de inmunoglobulina, en las cuales la secuencia amino de cada una de las dos cadenas pesadas es la secuencia de la SEQ ID Nº 3 y la secuencia de aminoácido de cada una de las dos cadenas ligeras es la secuencia de la SEQ ID Nº 4, y caracterizado porque comprende: a) cultivar la célula de mamífero de la reivindicación 11 o la célula de mamífero de la reivindicación 12 bajo condiciones de manera que el anticuerpo es expresado, y b) recuperar el anticuerpo expresado. Reivindicación 15: Un método para tratar una condición autoinmune en un paciente, caracterizado porque comprende administrar una dosis efectiva del anticuerpo de conformidad con cualquiera de las reivindicaciones 1 a 4 ó 14 al paciente. Reivindicación 24: Una composición farmacéutica caracterizada porque comprende el anticuerpo de conformidad con cualquiera de las reivindicaciones 1, 2, ó 12 y un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461968550P | 2014-03-21 | 2014-03-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR099625A1 true AR099625A1 (es) | 2016-08-03 |
Family
ID=54141466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150100643A AR099625A1 (es) | 2014-03-21 | 2015-03-04 | Anticuerpos de il-21 |
Country Status (24)
Country | Link |
---|---|
US (1) | US9394362B2 (es) |
EP (1) | EP3119806B1 (es) |
JP (2) | JP6053989B2 (es) |
KR (1) | KR101859857B1 (es) |
CN (1) | CN106061999B (es) |
AP (1) | AP2016009450A0 (es) |
AR (1) | AR099625A1 (es) |
AU (1) | AU2015231777B2 (es) |
BR (1) | BR112016019176A2 (es) |
CA (1) | CA2939543C (es) |
CL (1) | CL2016002281A1 (es) |
EA (1) | EA033335B1 (es) |
EC (1) | ECSP16075416A (es) |
ES (1) | ES2774422T3 (es) |
IL (1) | IL246909A0 (es) |
MA (1) | MA39342B2 (es) |
MX (1) | MX2016012120A (es) |
MY (1) | MY177915A (es) |
NZ (1) | NZ722518A (es) |
PE (1) | PE20161221A1 (es) |
PH (1) | PH12016501820A1 (es) |
SG (1) | SG11201606705QA (es) |
TW (1) | TWI646105B (es) |
WO (1) | WO2015142637A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2814150T3 (es) | 2014-04-08 | 2021-03-26 | Boston Pharmaceuticals Inc | Moléculas de unión específicas para IL-21 y usos de las mismas |
CN108472382A (zh) | 2015-10-30 | 2018-08-31 | 豪夫迈·罗氏有限公司 | 抗-因子d抗体变体缀合物及其用途 |
JP7010833B2 (ja) * | 2016-03-31 | 2022-02-10 | イーライ リリー アンド カンパニー | Il-21抗体及びその使用 |
JP2021526143A (ja) * | 2018-05-31 | 2021-09-30 | グリコム・アクティーゼルスカブGlycom A/S | 自己免疫疾患を処置するためのhmoの混合物 |
KR20210081322A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도 |
JP2022536898A (ja) | 2019-06-12 | 2022-08-22 | アスクジーン・ファーマ・インコーポレイテッド | 新規il-15プロドラッグおよびその使用方法 |
WO2021035188A1 (en) | 2019-08-21 | 2021-02-25 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
AU2022309028A1 (en) | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
JP2024525611A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス,インコーポレーテッド | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
MX2024000492A (es) * | 2021-07-09 | 2024-04-09 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para tratar las distrofinopatías. |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI9715219B8 (pt) * | 1996-02-09 | 2015-07-07 | Abbvie Biotechnology Ltd | Vetor recombinante de expressão, e célula hospedeira procariótica. |
JP4914209B2 (ja) | 2003-03-14 | 2012-04-11 | ワイス | ヒトil−21受容体に対する抗体および該抗体の使用 |
ITRM20040586A1 (it) * | 2004-11-29 | 2005-02-28 | Giuliani Spa | Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico. |
EP1963369B1 (en) * | 2005-11-28 | 2013-05-15 | Zymogenetics, Inc. | Il-21 antagonists |
CA2632218A1 (en) * | 2005-11-28 | 2007-10-11 | Zymogenetics, Inc. | Il-21 receptor antagonists |
US20090076249A1 (en) * | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
CN102027011B (zh) * | 2007-12-07 | 2014-09-03 | 津莫吉尼蒂克斯公司 | 抗人il-21单克隆抗体 |
WO2009071696A2 (en) * | 2007-12-07 | 2009-06-11 | Zymogenetics, Inc. | Humanized antibody molecules specific for il-31 |
EP2665750A1 (en) | 2011-01-17 | 2013-11-27 | Novo Nordisk A/S | Il-21 ligands |
WO2012164021A1 (en) * | 2011-05-31 | 2012-12-06 | Novo Nordisk A/S | Il-21 epitope and il-21 ligands |
-
2015
- 2015-03-04 AR ARP150100643A patent/AR099625A1/es unknown
- 2015-03-06 TW TW104107331A patent/TWI646105B/zh not_active IP Right Cessation
- 2015-03-13 PE PE2016001575A patent/PE20161221A1/es unknown
- 2015-03-13 US US14/657,075 patent/US9394362B2/en active Active
- 2015-03-13 MX MX2016012120A patent/MX2016012120A/es unknown
- 2015-03-13 SG SG11201606705QA patent/SG11201606705QA/en unknown
- 2015-03-13 JP JP2016514173A patent/JP6053989B2/ja active Active
- 2015-03-13 BR BR112016019176A patent/BR112016019176A2/pt not_active Application Discontinuation
- 2015-03-13 MY MYPI2016703395A patent/MY177915A/en unknown
- 2015-03-13 AP AP2016009450A patent/AP2016009450A0/en unknown
- 2015-03-13 CN CN201580012207.3A patent/CN106061999B/zh active Active
- 2015-03-13 WO PCT/US2015/020383 patent/WO2015142637A1/en active Application Filing
- 2015-03-13 MA MA39342A patent/MA39342B2/fr unknown
- 2015-03-13 CA CA2939543A patent/CA2939543C/en active Active
- 2015-03-13 EP EP15764397.4A patent/EP3119806B1/en active Active
- 2015-03-13 ES ES15764397T patent/ES2774422T3/es active Active
- 2015-03-13 AU AU2015231777A patent/AU2015231777B2/en not_active Ceased
- 2015-03-13 KR KR1020167025492A patent/KR101859857B1/ko active IP Right Grant
- 2015-03-13 NZ NZ722518A patent/NZ722518A/en not_active IP Right Cessation
- 2015-03-13 EA EA201691521A patent/EA033335B1/ru not_active IP Right Cessation
-
2016
- 2016-07-24 IL IL246909A patent/IL246909A0/en unknown
- 2016-09-09 CL CL2016002281A patent/CL2016002281A1/es unknown
- 2016-09-19 PH PH12016501820A patent/PH12016501820A1/en unknown
- 2016-09-20 EC ECIEPI201675416A patent/ECSP16075416A/es unknown
- 2016-11-29 JP JP2016231655A patent/JP6373944B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR099625A1 (es) | Anticuerpos de il-21 | |
JP2020500538A5 (es) | ||
AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
RU2019118359A (ru) | Антитело к cd73 человека | |
PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
AR105654A1 (es) | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) | |
PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
AR102239A1 (es) | Anticuerpos anti-ox40 humanizados y sus usos | |
AR111203A1 (es) | Inmunoconjugados | |
AR109715A1 (es) | Anticuerpos anti-cd27 | |
AR106752A1 (es) | Proteínas de unión a pd1 / ctla4 | |
AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
PE20170687A1 (es) | Proteinas de enlace a cd127 | |
PE20180120A1 (es) | Proteinas de union a icos | |
AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
PE20141660A1 (es) | PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA | |
RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
PE20161311A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. | |
AR097651A1 (es) | Métodos y composiciones que comprenden polipéptidos recombinantes purificados | |
NZ727024A (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
AR102592A1 (es) | Anticuerpos biespecíficos y métodos de uso en oftalmología | |
PE20161245A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |